

K'IMA:W MEDICAL CENTER COVID-19 UPDATE 1/17/23




COVID Cases To Date

- ❑ (1977)TOTAL CASES
- ❑ (9) ACTIVE CASES
- ❑ TOTAL HOSPITALIZATIONS: (43)
- ❑ CURRENT HOSPITALIZATIONS: (0)
- ❑ DEATHS: 4

COVID 19 Positive Cases

1/1/22 through 12/31/22



2022 COVID Totals

▣ 1,220 COVID Positives

2022

Covid/Respiratory Unit at KMC
saw

2824 Patients

Influenza and RSV

- ▣ Despite seeing lower positive cases of COVID, KMC is diagnosing many cases of Influenza and RSV (Respiratory Syncytial Virus)
- ▣ Last week many KMC staff or their families were affected by COVID, Influenza, or RSV.
- ▣ This left the clinic short-staffed, the Nursing Department alone was down 8 staff members.


North Coast Testing Partnership

- ▣ North Coast Testing Partnership offered Hoopa Valley Tribes COVID-19 Surveillance Testing at no cost.
- ▣ 10/31/22 NCTP Contract ended with the State.
- ▣ NCTP will no longer be offering COVID-19 Surveillance Testing Lab Services.

Surveillance Testing

- ▣ The current recommendation is not to do surveillance testing of unvaccinated individuals.
- ▣ What are the recommendations of the Hoopa Valley Tribe?
- ▣ Discussions are ongoing with Dr. Smith, Tribal Insurance, calls are into OES, and myself.

COVID 19 Positive Cases 4/2020 through 9/22



Seasonal Flu Vaccine

- ❑ KMC has the regular Flu Vaccine.
- ❑ Appointments are being made to receive the vaccine and see a provider at the same time.
- ❑ This will allow the provider to have an opportunity to see the patient and connect individuals with chronic disease processes to care, refer for labs, and connect to follow up care.
- ❑ Revenue will be generated by the appointment

Seasonal Flu Vaccine

- ❑ Flu Vaccine given at the Diabetes Walk on October 8, 2022. 43 Flu Vaccines given

Bivalent Booster Vaccine

- ▣ The bivalent COVID-19 vaccines, include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA components in common between the Omicron variant BA.4 and BA.5 to provide better protection against COVID-19 caused by the Omicron variant.

Moderna Bivalent Booster

Authorized uses:

- ▣ 6 months and above
- ▣ Completed a COVID vaccine primary dose series.
- ▣ Eligible if it has been 2 months since your primary 2 dose series.

Moderna

Moderna COVID-19 Vaccine At-A-Glance



Scheduling Doses

Graphics below provide an overview for the number of doses of vaccine based on the type of dose (primary versus booster), recipient's age and health status. Review [CDC's Interim COVID-19 Immunization Schedule](#) for detailed clinical guidance when scheduling doses

For Most Persons

Moderna
(ages 6 months–
4 years)



Moderna
(ages 5 years
and older)



For Moderately or Severely Immunocompromised Persons

Moderna
(ages 6 months–
4 years)



Moderna
(ages 5 years
and older)



* Administer an age-appropriate mRNA bivalent booster (i.e., Pfizer-BioNTech for people age 5 years and either Pfizer-BioNTech or Moderna for people ages 6 years and older). For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

Moderna

Moderna COVID-19 Vaccine

At-A-Glance



Preparation and Administration Basics

Find additional guidance on preparing and administering vaccine properly at:

- [Administration of Moderna COVID-19 Vaccines | CDC](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)
- [Vaccine Administration Resource Library | CDC](#)
- [Moderna COVID-19 Vaccines | FDA](#)
- [Moderna \(modernacovid19global.com\)](#)

Preparation

Vial cap color	Monovalent Blue Cap	Monovalent Blue Cap	Monovalent Red Cap	Bivalent Blue Cap
Ages	6 months through 5 years	6 through 11 years	12 years and older	6 years and older
Beyond-use date/time	After first puncture, use within 12 hours			
Do NOT use a punctured vial after 12 hours	If using a vial for the 1st time, record the date and time the vial was punctured. NOTE: The beyond-use time (12 hours) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use time has passed.			

Administration

- COVID-19 vaccine may be administered at the clinical visit as other vaccines.
- **Do not** "pool vaccine" from more than 1 vial to obtain a dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.

Recipient's Age	Use	Administer	Route	Needle gauge and length	Site
6 months through 5 years of age	Monovalent Blue capped vial with magenta-bordered label	Primary series: 25 µg/ 0.25 mL	IM injection	22-25 gauge, 1"	6 months – 2 years of age: Vastus lateralis muscle in the anterolateral thigh* 3 - 5 years of age: Deltoid muscle in the upper arm†
6 through 11 years	Monovalent Blue capped vial with purple-bordered label	Primary series: 50 µg/0.5 mL	IM Injection	22-25 gauge, 1"	Deltoid muscle in the upper arm†
12 years or older	Monovalent Red vial cap with blue-bordered label	Primary series: 100 µg/ 0.5 mL	IM injection	22-25 gauge, 1 – 1½"	Deltoid muscle in the upper arm†
6 years or older	Bivalent Dark blue capped vial with gray-bordered label	Booster dose only:	IM injection	22-25 gauge, 1 – 1½"	Deltoid muscle in the upper arm†
		6-11 years: 25 µg / 0.25 mL 12 years and older: 50 µg / 0.5 mL			

* The deltoid muscle in the upper arm may be used if the muscle mass is adequate.

† Vastus lateralis muscle in the anterolateral thigh may be used.

Pfizer Bivalent Booster

Authorized uses:

- ❑ 6 months of age and up
- ❑ Completed a COVID vaccine primary dose series.
- ❑ Eligible if it has been 2 months since your primary 2 dose series.
- ❑ KMC has Pfizer Bivalent Booster Vaccine

Pfizer

Pfizer-BioNTech COVID-19 Vaccine At-A-Glance



Scheduling Doses

Graphics below provide an overview for the number of doses of vaccine based on the type of dose (primary versus booster), recipient's age and health status. Review [CDC's Interim COVID-19 Immunization Schedule](#) for detailed clinical guidance when scheduling doses

For Most Persons

Pfizer-BioNTech
(ages 6 months–
4 years)



Pfizer-BioNTech
(Ages 5 years
and older)



For Moderately or Severely Immunocompromised Persons

Pfizer-BioNTech
(ages 6 months–
4 years)



Pfizer-BioNTech
(ages 5 years
and older)



* Administer an age-appropriate mRNA bivalent booster (i.e., Pfizer-BioNTech for people age 5 years and either Pfizer-BioNTech or Moderna for people ages 6 years and older). For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

Pfizer

Pfizer-BioNTech COVID-19 Vaccine At-A-Glance











Preparation and Administration Basics

Find additional guidance on preparing and administering vaccine properly at:

- Administration of Pfizer-BioNTech COVID-19 Vaccines | CDC
- Vaccine Administration Resource Library | CDC
- Pfizer-BioNTech COVID-19 Vaccines | FDA
- Pfizer-BioNTech COVID-19 Vaccine | cvdvaccine.com

Preparation

Vial cap color	 Monovalent Maroon Cap	 Monovalent Orange Cap	 Bivalent Orange Cap	 Monovalent Gray Cap	 Bivalent Gray Cap
Ages	6 months through 4 years	5 through 11 years		12 years and older	
Diluent*	2.2 mL per vial	1.3 mL per vial	1.3 mL per vial	 No diluent	 No diluent
Beyond-use date/time	After mixing with diluent, use within 12 hours.			After 1st puncture, use within 12 hours.	
 Do NOT use a punctured vial after 12 hours	If using a vial for the 1st time, record the date and time the vial was punctured. NOTE: The beyond-use time (12 hours) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use time has passed.				

* Diluent: Use sterile 0.9% sodium chloride (normal saline, preservative-free) included in the ancillary supply kit. Do not use bacteriostatic 0.9% sodium chloride or any other diluent.

Administration

- COVID-19 vaccine may be administered at the clinical visit as other vaccines.
- Do NOT "pool vaccine" from more than 1 vial to obtain a dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.

Recipient's Age	Use	Administer	Route	Needle gauge and length	Site
6 months through 4 years	Monovalent Maroon cap and maroon bordered label	Primary dose 3 µg/0.2 mL	IM injection	22–25 gauge, 1"	6 months – 2 years of age: Vastus lateralis muscle in the anterolateral thigh [†]
					3 years and older: Deltoid muscle in the upper arm [‡]
5 – 11 years	Monovalent Orange cap and orange bordered label	Primary dose 10 µg/0.2 mL	IM injection	22–25 gauge, 1"	Deltoid muscle in the upper arm [‡]
	Bivalent Orange cap and orange bordered label	Booster dose 10 µg/0.2 mL	IM injection	22–25 gauge, 1"	Deltoid muscle in the upper arm [‡]
12 years of age and older	Monovalent Gray cap and gray bordered label	Primary dose 30 µg/0.3 mL	IM injection	22–25 gauge, 1 – 1½"	Deltoid muscle in the upper arm [‡]
	Bivalent Gray cap and gray bordered label	Booster dose 30 µg/0.3 mL	IM injection	22–25 gauge, 1 – 1½"	Deltoid muscle in the upper arm [‡]

Monkeypox

Monkeypox is a disease caused by infection with the monkeypox virus. Monkeypox is part of the same family of viruses as the virus that causes smallpox.

Symptoms Include:

- ❑ Fever
- ❑ Chills
- ❑ Swollen Lymph Nodes
- ❑ Muscle Aches and Backpains
- ❑ Exhaustion
- ❑ Headache
- ❑ Respiratory symptoms, sore throat, nasal congestion, or cough.
- ❑ Rash, may initially look like pimples or blisters and may be painful or itchy.

Monkeypox

- ▣ How is Monkeypox spread:
- ▣ Skin to skin contact
- ▣ By touching objects, fabrics, surfaces that have been used by someone with monkeypox or by contact with respiratory secretions.

Monkeypox

Vaccine:

Jynneos Vaccine – FDA Approved

Eligibility: High Risk Population 18 years of age and older.

KMC has 16 doses available.

4 identified high risk patients will be scheduled per day to administer the vaccine.

TPOXX

Monkeypox Treatment

Humboldt County Health Department has housed 1 course of TPOXX treatment with Kimaw Medical Center, in the event that an individual in our KT area develops monkeypox.

Post COVID-19 Conditions

“Long COVID”

- ▣ Individuals can experience returning illness, recurring health problems, or a range of new symptoms four or more weeks after having COVID-19. This is referred to as post-COVID conditions.
- ▣ Anyone can develop post-COVID conditions including those that were asymptomatic or had mild symptoms.

Long COVID Symptoms

- Brain Fog
 - Difficulty breathing or shortness of breath
 - Post-exertional malaise
 - Cough
 - Chest or stomach pain
 - Headache
 - Heart palpitations
 - Joint or muscle pain
 - Multiorgan Effects (including heart, lung, kidney, skin, and brain functions)
 - Pins-and-needles feeling
 - Diarrhea
 - Sleep problems
 - Fever
 - Lightheadedness
 - Rash
 - Mood Changes
 - Changes in menstrual Period Cycle
- ❑ 10% to 30% of COVID-19 positive patients experience the after effects of the virus.

COVID Therapeutics

Evushield

- ❖ IM Therapy
- ❖ K'ima:w Medical Center

➤ Paxlovid


- ❖ Oral Therapy
- ❖ K'ima:w Medical Center

COVID Vaccine & Boosters Available at KMC

- ▣ Vaccine & Booster Clinics

Thursdays Children
6 months to 17 yrs
Fridays Adults

- ▣ By Appointment Call:
 - ▣ 530-625-4261
 - ▣ Ext. 0221 or 0259



COVID Testing Options

Effective January 19th order free home Covid19 tests:

<http://www.covidtesting.gov>



TODAY.COM

How to order free at-home COVID-19 tests from the governm...

KMC

Monday-Friday 8:40-4:30

By appointment

625-4261 Ext 0218

OptumServe

Thursdays 10:00-3:00

Hoopa Fire Department

Home Test Available

Limited supply of Quidel COVID Home Tests Available

<https://quickvueathome.com/>



FAST. EASY. READY WHEN YOU ARE.

2 TESTS

QuickVue[®] At-Home OTC COVID-19 Test

- Two (2) tests with simple instructions
- The test is intended to be used twice over two to three days, with at least 24 hours and no more than 36 hours between tests.
- Dos (2) pruebas con instrucciones sencillas
- La prueba está diseñada para usarse dos veces durante dos o tres días, con al menos 24 horas y no más de 36 horas entre pruebas.

RAPID RESULTS IN 10 MIN

may vary.

For use under FDA Emergency